Fosamax (alendronate) to be promoted to PREVENT osteoporosis

    The FDA will soon allow Fosamax (alendronate) to be promoted to PREVENT osteoporosis. It was originally approved for treatment.

    Fosamax slows bone loss and increases bone density. It reduces hip fractures by 50% in women who already have osteoporosis.

    Now it'll also be used for women who are at risk because of early menopause...thin build...Caucasian or Asian race...family history...or a low bone density.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote